EPS for Summit Therapeutics plc (SMMT) Expected At $-0.77

March 14, 2018 - By Kurt Siggers

 EPS for Summit Therapeutics plc (SMMT) Expected At $ 0.77

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.77 EPS on April, 4.They anticipate $0.27 EPS change or 54.00 % from last quarter’s $-0.5 EPS. After having $-0.20 EPS previously, Summit Therapeutics plc’s analysts see 285.00 % EPS growth. The stock increased 1.16% or $0.16 during the last trading session, reaching $13.9. About 61,222 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since March 14, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 8 analysts covering Summit Therapeutic (NASDAQ:SMMT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Summit Therapeutic had 13 analyst reports since August 19, 2015 according to SRatingsIntel. Canaccord Genuity maintained the stock with “Buy” rating in Tuesday, March 6 report. The firm has “Buy” rating given on Friday, December 1 by H.C. Wainwright. As per Friday, September 16, the company rating was initiated by H.C. Wainwright. The stock of Summit Therapeutics plc (NASDAQ:SMMT) has “Hold” rating given on Tuesday, September 1 by Zacks. As per Thursday, June 15, the company rating was maintained by Canaccord Genuity. H.C. Wainwright maintained Summit Therapeutics plc (NASDAQ:SMMT) rating on Thursday, July 6. H.C. Wainwright has “Buy” rating and $2600 target. The stock has “Buy” rating by Janney Capital on Tuesday, June 21. RBC Capital Markets maintained the shares of SMMT in report on Wednesday, November 16 with “Outperform” rating. Oppenheimer maintained it with “Buy” rating and $2400 target in Thursday, June 22 report. The firm has “Buy” rating by Oppenheimer given on Wednesday, August 19.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $202.42 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: Quotes.Wsj.com which released: “Summit Therapeutics PLC ADR SMMT (US: Nasdaq)” on February 13, 2011. Also Marketwatch.com published the news titled: “Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta” on October 04, 2016. Marketwatch.com‘s news article titled: “Summit Therapeutics PLC ADR” with publication date: June 26, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.